GlassScriptPhysician profile
Romy Abou Mrad
NPI 1851655518
$17,994.63
in general payments reported to CMS, 2019-2025
20 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $2,021 · 2021: $985 · 2022: $82.73 · 2023: $11K · 2024: $1,735 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,813 · Food and Beverage: $3,535 · Travel and Lodging: $885 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,812.50 |
| Food and Beverage | $3,534.71 |
| Travel and Lodging | $885.18 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,874.58 | 2019-2023 | Krystexxa |
| Abbvie INC. | $995.14 | 2019-2024 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $855.81 | 2019-2024 | Enbrel, Krystexxa, Tavneos |
| Pfizer INC. | $816.64 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $475.62 | 2019-2025 | |
| Janssen Biotech, INC. | $433.36 | 2019-2024 | Tremfya, Simponi Aria |
| Ucb, INC. | $379.08 | 2019-2024 | Cimzia |
| Lilly USA, LLC | $340.30 | 2019-2024 | Taltz, Zepbound |
| Genentech USA, INC. | $159.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $155.88 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $146.64 | 2024-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $118.99 | 2019-2024 | Orencia |
| Ani Pharmaceuticals, INC. | $72.58 | 2023-2024 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $48.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $19.20 | 2024 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $18.46 | 2023 | Arcalyst |
| Mallinckrodt Enterprises LLC | $18.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2024 | Ofev |
| Kiniksa Pharmaceuticals International, Plc | $15.70 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romy Abou Mrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.